|
|
||||||||
Investigative Ophthalmology & Visual Science, Vol 38, 741-752, Copyright © 1997 by Association for Research in Vision and Ophthalmology
ARTICLES AND REPORTS |
R Goralczyk, S Buser, J Bausch, W Bee, U Zuhlke and FM Barker
Department of Exploratory Research, F. Hoffmann-La Roche AG, Basel, Switzerland.
PURPOSE: To reproduce and investigate in a primate animal model the phenomenon of the red carotenoid canthaxanthin (beta, beta-carotene- 4'4'-dione) to induce crystal-like retinal deposits as they have been observed in the ocular fundus of humans after high canthaxanthin intake (i.e., more than 30 mg/day). METHODS: Groups of four cynomolgus monkeys (Macaca fascicularis) per gender and dose were administered 5.4, 16.2, or 48.6 mg canthaxanthin/kg body weight daily by oral gavage for 2.5 years. Eight control animals received placebo. In vivo ophthalmoscopy was performed at intervals of 3 months along with electroretinography after 12 and 24 months and retinal biomicroscopy just before the monkeys were killed. Retinal wholemounts or frozen sections were investigated postmortem by polarization, bright field, and differential interference contrast microscopy. Retinal and preterminal plasma canthaxanthin concentrations were determined by high-performance liquid chromatography (HPLC). RESULTS: By ophthalmoscopy and retinal biomicroscopy in vivo, no crystals or other light-reflecting particles were observed in the central paramacular retina. However, postmortem polarization microscopy of all 24 canthaxanthin-treated animals showed a circular zone in the peripheral retina containing birefringent, polymorphous red, orange, or white inclusions. The density of these inclusions was diminished within 1 to 8 mm posterior to the ora serrata. These inclusions were located mainly in the inner retinal layers, that is the nerve fiber layer and ganglion cell layer, inner plexiform layer, and inner nuclear layer. Twelve of the 24 canthaxanthin-treated animals showed yellow, golden birefringent inclusions in the macula. Retinas of placebo-treated monkeys were free of birefringent, crystal-like inclusions. The HPLC confirmed the presence of all-trans canthaxanthin, and 4-OH-echinenone and isozeaxanthin as well, in the retinas of all canthaxanthin-treated animals. Neither electroretinography nor histopathology indicated any adverse effects of the canthaxanthin-induced retinal inclusions seen in this study. CONCLUSIONS: A high intake of canthaxanthin for 2.5 years led to the deposition of crystal-like birefringent inclusions in the inner layers of the peripheral retina and, to some extent, the central retina of cynomolgus monkeys. The presence of these deposits did not interfere with morphology nor with retinal function.
This article has been cited by other articles:
![]() |
P. Charbel Issa, T. T. J. M. Berendschot, G. Staurenghi, F. G. Holz, and H. P. N. Scholl Confocal Blue Reflectance Imaging in Type 2 Idiopathic Macular Telangiectasia Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1172 - 1177. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Hannibal, J. Lorquin, N. A. D'Ortoli, N. Garcia, C. Chaintreuil, C. Masson-Boivin, B. Dreyfus, and E. Giraud Isolation and Characterization of Canthaxanthin Biosynthesis Genes from the Photosynthetic Bacterium Bradyrhizobium sp. Strain ORS278 J. Bacteriol., July 1, 2000; 182(13): 3850 - 3853. [Abstract] [Full Text] |
||||
![]() |
R. Goralczyk, F. M. Barker, S. Buser, H. Liechti, and J. Bausch Dose Dependency of Canthaxanthin Crystals in Monkey Retina and Spatial Distribution of its Metabolites Invest. Ophthalmol. Vis. Sci., May 1, 2000; 41(6): 1513 - 1522. [Abstract] [Full Text] |
||||
![]() |
A. Espaillat, L. P. Aiello, P. G. Arrigg, R. Villalobos, P. M. Silver, and R. W. Cavicchi Canthaxanthine Retinopathy Arch Fam Med, February 1, 2000; 9(2): 121 - 122. [Full Text] [PDF] |
||||
![]() |
A. Espaillat, L. P. Aiello, P. G. Arrigg, R. Villalobos, P. M. Silver, and R. W. Cavicchi Canthaxanthine Retinopathy Arch Ophthalmol, March 1, 1999; 117(3): 412 - 413. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |